Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
Wellgistics Health (NASDAQ: WGRX) has announced a strategic partnership through its subsidiary Wellgistics with Tollo Health to market novel medical food products targeting two key markets: GLP-1 treatment side effects and Long COVID symptoms.
The agreement focuses on distributing Tollo's proprietary products, including Galectovid™, to address issues such as muscle loss and gut discomfort associated with GLP-1 drug use, as well as various Long COVID symptoms. The partnership aims to leverage Wellgistics' pharmacy network to distribute these medical foods, which are designed to be taken under physician supervision.
The initiative targets significant market opportunities: The GLP-1 drug market is currently valued at $46.7 billion and projected to reach $322 billion by 2034. Additionally, with approximately 16 million working-age Americans affected by Long COVID, resulting in estimated lost wages of $170 billion annually, the partnership positions Wellgistics to address substantial unmet medical needs.
Wellgistics Health (NASDAQ: WGRX) ha annunciato una partnership strategica attraverso la sua controllata Wellgistics con Tollo Health per commercializzare nuovi prodotti alimentari medici mirati a due mercati chiave: gli effetti collaterali del trattamento con GLP-1 e i sintomi del Long COVID.
L'accordo si concentra sulla distribuzione dei prodotti proprietari di Tollo, tra cui Galectovid™, per affrontare problemi come la perdita di massa muscolare e il disagio gastrointestinale associati all'uso di farmaci GLP-1, oltre a vari sintomi del Long COVID. La partnership mira a sfruttare la rete di farmacie di Wellgistics per distribuire questi alimenti medici, progettati per essere assunti sotto supervisione medica.
L'iniziativa punta a significative opportunità di mercato: il mercato dei farmaci GLP-1 è attualmente valutato 46,7 miliardi di dollari e si prevede che raggiunga 322 miliardi di dollari entro il 2034. Inoltre, con circa 16 milioni di americani in età lavorativa colpiti dal Long COVID, che comportano una perdita di salari stimata di 170 miliardi di dollari all'anno, la partnership posiziona Wellgistics per affrontare esigenze mediche sostanziali non soddisfatte.
Wellgistics Health (NASDAQ: WGRX) ha anunciado una asociación estratégica a través de su subsidiaria Wellgistics con Tollo Health para comercializar nuevos productos alimenticios médicos dirigidos a dos mercados clave: los efectos secundarios del tratamiento con GLP-1 y los síntomas del Long COVID.
El acuerdo se centra en la distribución de los productos patentados de Tollo, incluido Galectovid™, para abordar problemas como la pérdida de masa muscular y el malestar gastrointestinal asociados con el uso de medicamentos GLP-1, así como varios síntomas del Long COVID. La asociación tiene como objetivo aprovechar la red de farmacias de Wellgistics para distribuir estos alimentos médicos, que están diseñados para ser consumidos bajo supervisión médica.
La iniciativa apunta a oportunidades de mercado significativas: el mercado de medicamentos GLP-1 está actualmente valorado en 46.7 mil millones de dólares y se proyecta que alcance 322 mil millones de dólares para 2034. Además, con aproximadamente 16 millones de estadounidenses en edad laboral afectados por Long COVID, lo que resulta en una pérdida de salarios estimada de 170 mil millones de dólares anuales, la asociación posiciona a Wellgistics para abordar necesidades médicas no satisfechas sustanciales.
웰기스틱스 헬스 (NASDAQ: WGRX)는 자회사 웰기스틱스를 통해 톨로 헬스와 전략적 파트너십을 체결하여 GLP-1 치료 부작용과 롱 COVID 증상을 겨냥한 새로운 의료식품 제품을 마케팅할 것이라고 발표했습니다.
이번 협정은 GLP-1 약물 사용과 관련된 근육 손실 및 장 불편감 같은 문제를 해결하기 위해 톨로의 독점 제품, 특히 갈렉토비드™의 유통에 중점을 두고 있습니다. 또한 다양한 롱 COVID 증상도 포함됩니다. 파트너십은 웰기스틱스의 약국 네트워크를 활용하여 이러한 의료식품을 배급하는 것을 목표로 하며, 의사의 감독 하에 섭취하도록 설계되었습니다.
이 이니셔티브는 중요한 시장 기회를 겨냥하고 있습니다: GLP-1 약물 시장은 현재 467억 달러로 평가되며, 2034년까지 3,220억 달러에 이를 것으로 예상됩니다. 또한, 약 1,600만 명의 근무 연령 미국인이 롱 COVID의 영향을 받고 있으며, 이로 인해 연간 1,700억 달러의 임금 손실이 추정되고 있어, 웰기스틱스는 상당한 unmet medical needs에 대응할 수 있는 위치에 있습니다.
Wellgistics Health (NASDAQ: WGRX) a annoncé un partenariat stratégique à travers sa filiale Wellgistics avec Tollo Health pour commercialiser de nouveaux produits alimentaires médicaux ciblant deux marchés clés : les effets secondaires du traitement par GLP-1 et les symptômes du Long COVID.
L'accord se concentre sur la distribution des produits propriétaires de Tollo, y compris Galectovid™, pour traiter des problèmes tels que la perte de muscle et l'inconfort intestinal associés à l'utilisation de médicaments GLP-1, ainsi que divers symptômes du Long COVID. Le partenariat vise à tirer parti du réseau de pharmacies de Wellgistics pour distribuer ces aliments médicaux, qui sont conçus pour être pris sous supervision médicale.
L'initiative cible des opportunités de marché significatives : le marché des médicaments GLP-1 est actuellement évalué à 46,7 milliards de dollars et devrait atteindre 322 milliards de dollars d'ici 2034. De plus, avec environ 16 millions d'Américains en âge de travailler touchés par le Long COVID, entraînant des pertes de salaires estimées à 170 milliards de dollars par an, le partenariat positionne Wellgistics pour répondre à des besoins médicaux non satisfaits considérables.
Wellgistics Health (NASDAQ: WGRX) hat eine strategische Partnerschaft über ihre Tochtergesellschaft Wellgistics mit Tollo Health angekündigt, um neuartige medizinische Lebensmittelprodukte zu vermarkten, die zwei Schlüsselbereiche ansprechen: Nebenwirkungen der GLP-1-Behandlung und Symptome von Long COVID.
Der Vertrag konzentriert sich auf die Verteilung von Tollos proprietären Produkten, einschließlich Galectovid™, um Probleme wie Muskelverlust und Magenbeschwerden im Zusammenhang mit der Verwendung von GLP-1-Arzneimitteln sowie verschiedene Symptome von Long COVID anzugehen. Die Partnerschaft zielt darauf ab, das Apothekennetzwerk von Wellgistics zu nutzen, um diese medizinischen Lebensmittel zu vertreiben, die unter ärztlicher Aufsicht eingenommen werden sollen.
Die Initiative zielt auf bedeutende Marktchancen ab: Der Markt für GLP-1-Arzneimittel wird derzeit auf 46,7 Milliarden Dollar geschätzt und soll bis 2034 auf 322 Milliarden Dollar anwachsen. Darüber hinaus sind etwa 16 Millionen Amerikaner im erwerbsfähigen Alter von Long COVID betroffen, was zu geschätzten jährlichen Lohnverlusten von 170 Milliarden Dollar führt. Die Partnerschaft positioniert Wellgistics, um erhebliche unbefriedigte medizinische Bedürfnisse zu adressieren.
- Partnership grants access to $46.7B GLP-1 market
- Expansion into untapped Long COVID market affecting 16M Americans
- Cross-selling opportunity to existing pharmacy network
- Products backed by peer-reviewed clinical studies
- No approved prescription treatment options currently available
- Dependent on physician adoption and recommendation
- Competitive market with established players
- Medical foods typically generate lower margins than prescription drugs
Insights
Wellgistics Health (NASDAQ: WGRX) has entered a strategic agreement that positions the company to capitalize on two substantial healthcare opportunities: the $46.7 billion GLP-1 drug market (projected to reach $322 billion by 2034) and the Long COVID market affecting approximately 16 million working-age Americans.
This partnership with Tollo Health represents a calculated move into the medical foods segment, which occupies a unique regulatory position between prescription drugs and supplements. Medical foods require physician supervision but face fewer regulatory hurdles than pharmaceuticals, potentially enabling faster market entry and adoption. Tollo's first product, Galectovid™, targets galectin-associated viral infections, while their pipeline addresses muscle loss (sarcopenia) from GLP-1 medications and multiple Long COVID symptoms.
The strategic rationale appears twofold: First, it allows Wellgistics to offer solutions for conditions lacking FDA-approved treatments, potentially strengthening relationships with their pharmacy network. Second, it creates a cross-selling opportunity that could expand their customer base while positioning them as a specialized supplier in emerging healthcare markets.
Key considerations for investors include:
- Revenue timeline remains unclear - the announcement doesn't specify when material financial impact might be expected
- Market penetration potential depends heavily on physician education and adoption rates
- Insurance reimbursement for medical foods typically presents challenges that could limit patient access
- Competitive differentiation will be critical as other companies target these lucrative markets
This agreement aligns with Wellgistics' stated strategy as a healthcare technology and pharmaceutical services holding company, potentially creating new revenue streams through their existing distribution infrastructure without significant capital investment.
Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC (“Tollo”) to market Tollo’s emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and persistent viral infection(s), gut discomfort, sarcopenia, immune dysregulation, cellular senescence, endothelial damage and general nutritional support for patients with Long COVID. Tollo’s first marketed product is Galectovid™, a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections. Further details on Galectovid™ are available at www.galectovid.com.
“We are excited to partner with the team at Tollo, who bring in-depth scientific and medical knowledge in both the areas of muscle loss and chronic viral infections”, said Jason Lang, Vice President of Business Development of Wellgistics LLC. “We believe that our expansion into medical foods will directly impact our pharmacy clients and support physicians and the patients they serve. Managing the side effects of GLP-1 drugs and the devastating impacts of Long COVID remains a challenge because there are no approved prescription treatment options currently available. It only makes sense to look at natural products, backed by cutting edge scientific research, with no known side effects, to help manage these conditions. We recognize that sometimes medical foods are the only viable solutions to help our clients improve patient outcomes. We plan to work with Tollo and our clients to generate industry leading data on Tollo’s suite of products and make them broadly available to the pharmacies in our network. We expect this cross-selling strategy to help grow our customer base and position us as the key supplier for healthcare professionals in the GLP-1 and Long COVID markets.”
As part of the agreement, Tollo will assist Wellgistics LLC in preparing materials to market Tollo’s emerging suite of products to Wellgistics LLC’s network of pharmacies by generating healthcare practitioner-tailored content to help them educate client physicians, physician groups and patients on how to optimize patient outcomes by incorporating these select medical foods into patients’ treatment regimens. Medical foods are specialized foods, to be taken under the supervision of a physician, that are for the dietary management of certain health conditions. Wellgistics LLC’s objective of marketing Tollo’s medical foods is to provide patients with the dietary support they need to get the most out of prescription drugs and other treatment modalities used by their physicians to help manage complex chronic conditions.
“Given Wellgistics LLC’s innovative model of getting information directly into the hands of pharmacists and physicians who are treating complex conditions such as GLP-1 side effects and Long COVID, we believe they serve as the ideal partner to help drive adoption in the healthcare practitioner market as we roll out our suite of medical foods in the United States,” said Gerald Commissiong, CEO of Tollo. “We look forward to bringing our natural medical food products to the physicians and patients in Wellgistics LLC’s network that are desperately looking for a solution to address the significant side effects associated with GLP-1 use and the devastating impacts of Long COVID.”
The market for GLP-1 drugs is
About Wellgistics Health, Inc.
Wellgistics Health, Inc. is a holding company for existing and future planned operating companies centered around healthcare technology and pharmaceutical services. It seeks to be a micro health ecosystem, with a portfolio of companies consisting of a technology platform, pharmacy, and wholesale operations that provide novel prescription hub and clinical services. The Company is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, the Company intends to shift the dynamic of pharmaceutical care to revolve around the patient for a wide range of therapeutic conditions by offering a full spectrum of integrated solutions as a result of leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from “specialty-lite” to general maintenance conditions. Wellgistics LLC is a wholly owned subsidiary of the Company, focusing on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies. For more information, please visit the Company’s website at www.wellgisticshealth.com and Wellgistics LLC’s website at www.wellgistics.com.
About Tollo Health, LLC
Tollo Health, LLC is a medical foods company seeking to bring to market proprietary formulations for the dietary management of GLP-1 treatment-related side effects and viral conditions that include Long COVID under the supervision of a physician. In this regard, Tollo aims to bring to market a full range of products that will provide patients with functional relief from these devastating health conditions by addressing the key biological mechanisms driving poor patient outcomes. By using natural products tailored with proprietary formulations that deliver the key nutrients needed to alter the negative feedback loops often associated with chronic conditions, Tollo aims to fill a gap currently not served by certain prescription drugs. For more information, please visit Tollo’s website at www.tollohealth.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the benefits of Tollo’s medical foods as well as the Company’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to the Company’s ability to meet distribution expectations and projections, certain market conditions, and other factors discussed in the Company’s filings with the SEC, including its Current Reports on Form 8-K and in the section entitled “Risk Factors” of the registration statement on Form S-1 initially filed with the SEC on July 22, 2024, as subsequently amended. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
FAQ
What is the market potential for WGRX's new medical food products partnership?
What specific products will WGRX distribute through the Tollo Health partnership?
How will the Tollo Health agreement benefit WGRX's business model?
What is the scientific basis for WGRX's new medical food products?
